BioTuesdays

Ritter Pharma engages AGP to explore strategic alternatives

Ritter Pharmaceuticals (NASDAQ:RTTR) has engaged Alliance Global Partners as a financial advisor to help the company evaluate strategic alternatives. 

The company is considering a variety of options, including an acquisition, merger, reverse merger, other business combination, sale of assets, licensing or other strategic transactions. 

On Sept. 12, the company reported that its Phase 3 clinical trial of RP-G28 for the treatment of lactose intolerance failed to demonstrate statistically significant symptom improvements compared to placebo.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.